CX3CL1/CX3CR1在脑缺血中的作用及其机制被引量：1

Effect of CX3CL1/CX3CR1 in cerebral ischemia and its mechanisms

导出

摘要 CX3CL1亦称分形趋化因子,是趋化因子CX3C亚类中的唯一成员,通过与其特异性受体CX3CR1结合,在多种中枢神经系统疾病和缺血性脑血管病中发挥重要作用。近年来,大量研究对CX3CL1/CX3CR1的具体作用和相关分子机制进行了探讨。本文就CX3CL1/CX3CR1在缺血性脑血管病中的作用和相关分子机制进行综述,旨在拓展对CX3CL1/CX3CR1作用机制的认识,为缺血性脑血管病的预防、诊断及治疗提供新的思路与干预靶点。 CX3CL1,also known as Fractalkine,is the only member of chemokines CX3C subclass.It plays an important role in a variety of central nervous system diseases and ischemic cerebrovascular diseases by binding to its specific receptor CX3CR1.In recent years,a large number of studies have investigated the specific role and related molecular mechanism of CX3CL1/CX3CR1.This article reviews the effect and molecular mechanism of CX3CL1/CX3CR1 in ischemic cerebrovascular disease,aiming to expand the understanding of the mechanism of CX3CL1/CX3CR1,and provide new ideas and intervention targets for the prevention,diagnosis and treatment of ischemic cerebrovascular disease.

作者杨桐李琼杨海梅朱洁李敬诚张莉莉 Yang Tong;Li Qiong;Yang Haimei;Zhu Jie;Li Jingcheng;Zhang Lili(Unit 93046 of the People's Liberation Army,Qingdao 266000,China;Department of Neurology,Army Characteristic Medical Center,Army Medical University,Chongqing 400042,China)

机构地区中国人民解放军陆军军医大学陆军特色医学中心神经内科

出处《国际脑血管病杂志》 2021年第7期537-543,共7页 International Journal of Cerebrovascular Diseases

基金国家自然科学基金(81771287)。

关键词缺血性脑血管病 CX3CR1 中枢神经系统疾病脑缺血趋化因子作用及其机制分子机制诊断及治疗 Brain ischemia Chemokine CX3CL1 CX3C chemokine receptor 1

分类号 R743.3 [医药卫生—神经病学与精神病学]

引文网络
相关文献

参考文献4

1Hong-Yun He,Lu Ren,Tao Guo,Yi-Hao Deng.Neuronal autophagy aggravates microglial inflammatory injury by downregulating CX3CL1/fractalkine after ischemic stroke[J].Neural Regeneration Research,2019,14(2):280-288. 被引量：30
2马志,朱沂,补娟.缺血性卒中后小胶质细胞介导的炎性信号通路[J].国际脑血管病杂志,2017,25(2):174-178. 被引量：6
3吴丽娥,乌兰.Fractalkine及其受体CX3CR1与脑血管病[J].国际脑血管病杂志,2010,18(2):142-145. 被引量：2
4郑剑华,陈晓辉,徐恩.趋化因子CX3CL1在脑缺血中的作用及机制[J].国际脑血管病杂志,2019,27(9):706-710. 被引量：2

二级参考文献24

1White GE, Greases DR. Fractalkine: one chemokine,many functions. Blood, 2009, 113: 767-768.
2Umehara H, Bloom ET, Okazaki T, et al. Fractalkine in vascular biology: from basic research to clinical disease. Arterioscler Thromb Vasc Biol, 2004, 24: 34--40.
3Sorimo SG.A,aravoadi LS,Wang YF,et al.Mice deficient in fractalkine are less susceptible to cerebral ischemia-reperfusion injury.J Neuroimmunol,002, 125: 59-65.
4Owlasiuk P,Zajkowska JM,Pietruczuk M,et al.Fractalkine-structure,functions and biological activity.pol Merkur Lekarski, 2009, 26: 253- 257.
5Chu L, Li X, Yu W, et al. Expression of fractalkine (CX3CL1) and its receptor in endotoxin-induced uveitis. Ophthalmic Res, 2009, 42: 160-166.
6Cartier L, Hartley O, Dubis-Dauphin M, et al. Chemokine receptors in the central nervous system: role in train inflammation and netrodegen- erative diseases. Brain Res Brain Res Rev, 2005, 48: 16-42.
7Wang Q, Tang XN, Yenan MA.The inflammatory response in stroke. J Neuroimmunol, 2007, 184: 53-68.
8Dorgham K, Ghadiri A, Hermand P, et al. An engineered CX3CR1 antagonist endowed with anti-inflammatory activity. J Leukoc Biol, 2009, 86:903-911.
9Denes A,Thornton P.Rothwell NJ,et al.Inflammation and brain injury:Acute cerebral ischaemia,peripheral and central inflammation.Brain Behav Immun 2009,Sep 19.[Epub aheab of print].
10Tarozzo G,Campanella M,Ghiani M,et al.Expression of fractlkine and its receptor,CX3CR1,in response to ischaemina-reperfusion brain injiury in the rat. Eur J Neurosei, 2002, 15: 1663-1668.